BriaCell - Protein Kinase C delta (PKCd) Inhibitors

Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors. This target has an attractive safety profile based on in vivo studies and knock out mouse studies. PKCδ also has potential activity as an immunotherapeutic by blocking TGFβ signaling. PKCδ inhibitors are applicable to specific niche tumor types which provide an accelerated clinical development plan. Could be in clinic within 24 months. Provides Cost-Effective Additional Shot-on-Goal and additional partnership opportunities.